Literature DB >> 36175634

Characterization of Human Parainfluenza Virus Receptor Using Terminal Sialic Acid Linkage-Modified Cells.

Keijo Fukushima1,2, Tadanobu Takahashi1, Takashi Suzuki3.   

Abstract

Human parainfluenza virus type 1 (hPIV1) and type 3 (hPIV3) are respiratory pathogen viruses that bind to terminal sialic acids of glycoconjugates on the cell surface hemagglutinin-neuraminidase glycoprotein. Sialic acid residues are linked to the galactose residue primarily by α2,3 or α2,6 linkages on the terminal of glycoprotein or glycolipids. One of the major determinants of pathogenicity or tissue tropism is virus binding or infection specificity for each sialyl linkage. Sialic linkage-modified human blood cells or mammalian cells that mainly have α2,3- or α2,6-linked sialic acid residues on the surface can be prepared by treatment with linkage-specific sialidases or sialyltransferases. These linkage-modified cells can be used in hemagglutination assays to estimate virus particles' binding specificity, hemadsorption assays to estimate virus glycoproteins' binding specificity, and virus infectivity assays. These methods contribute to identifying the specificity of sialic acid lineage recognition of the hPIV or other sialic acid-binding viruses.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Hemagglutinin-neuraminidase glycoprotein; Human parainfluenza virus; Sialic linkage; Sialidase; Sialyltransferase; Virus binding; Virus infection

Mesh:

Substances:

Year:  2022        PMID: 36175634     DOI: 10.1007/978-1-0716-2635-1_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  Uptake of sialic acid by human erythrocyte. Characterization of a transport system.

Authors:  Tatiana Bulai; Daniela Bratosin; Vlad Artenie; Jean Montreuil
Journal:  Biochimie       Date:  2003 Jan-Feb       Impact factor: 4.079

2.  Amino acid substitutions contributing to α2,6-sialic acid linkage binding specificity of human parainfluenza virus type 3 hemagglutinin-neuraminidase.

Authors:  Keijo Fukushima; Tadanobu Takahashi; Hiroo Ueyama; Masahiro Takaguchi; Seigo Ito; Kenta Oishi; Akira Minami; Erika Ishitsubo; Hiroaki Tokiwa; Toru Takimoto; Takashi Suzuki
Journal:  FEBS Lett       Date:  2015-04-11       Impact factor: 4.124

3.  On-line nano-HPLC/ESI QTOF MS monitoring of alpha2-3 and alpha2-6 sialylation in granulocyte glycosphingolipidome.

Authors:  Stephan Kirsch; Johannes Müthing; Jasna Peter-Katalinić; Laura Bindila
Journal:  Biol Chem       Date:  2009-07       Impact factor: 3.915

4.  Terminal sialic acid linkages determine different cell infectivities of human parainfluenza virus type 1 and type 3.

Authors:  Keijo Fukushima; Tadanobu Takahashi; Seigo Ito; Masahiro Takaguchi; Maiko Takano; Yuuki Kurebayashi; Kenta Oishi; Akira Minami; Tatsuya Kato; Enoch Y Park; Hidekazu Nishimura; Toru Takimoto; Takashi Suzuki
Journal:  Virology       Date:  2014-08-21       Impact factor: 3.616

5.  Isolation of paramyxovirus glycoproteins. Association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein.

Authors:  A Scheid; L A Caliguiri; R W Compans; P W Choppin
Journal:  Virology       Date:  1972-12       Impact factor: 3.616

6.  Receptor specificities of human respiroviruses.

Authors:  T Suzuki; A Portner; R A Scroggs; M Uchikawa; N Koyama; K Matsuo; Y Suzuki; T Takimoto
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 7.  Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses.

Authors:  Yasuo Suzuki
Journal:  Biol Pharm Bull       Date:  2005-03       Impact factor: 2.233

Review 8.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

9.  Purification, cloning, and expression of an alpha/beta-galactoside alpha-2,3-sialyltransferase from a luminous marine bacterium, Photobacterium phosphoreum.

Authors:  Hiroshi Tsukamoto; Yoshimitsu Takakura; Takeshi Yamamoto
Journal:  J Biol Chem       Date:  2007-08-16       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.